Research in nanotechnology has shown that nanometer sized particles can offer promising solutions for the delivery of drugs and biomolecules. Through the synergy of multidisciplinary expertise, lipidic nanoparticles, specifically plant virus nanoparticles and plant assembled virus-like particles, represent ideal candidates for several biomedical applications.
Through an integrated, multidisciplinary approach, we develop and test innovative protocols for the treatment of oncological and neurodegenerative diseases. Specifically, we use nanosecond pulsed electric fields (nsPEF) in combination with innovative drugs and ionizing radiation to enhance their efficacy. The effects of combining physical and pharmacological therapies are tested both in vitro and in vivo models to precisely evaluate their biological impact and therapeutic effectiveness.
The development of non-viral gene therapies represents an innovative and safe approach for the treatment of genetic diseases. Our strategy is based on the use of engineered DNA or microRNA sequences delivered to target tissues via pulsed electric fields (Electro Gene Transfer, EGT), with the aim of correcting genetic alterations or finely regulating gene expression.
To evaluate cellular responses to agents that affect human health and to develop innovative and personalized therapies, we employ biological systems of increasing complexity, ranging from cell cultures to organoids, and including murine models of human diseases such as colitis, ocular disorders, cardiovascular diseases, neurodegenerative diseases, and cancer.
An emerging area in medicine is the combined use of electronic devices and electromagnetic fields for the treatment of oncological and nervous system disorders. This approach offers several advantages, including a reduction in side effects.
The need for non-invasive techniques for clinical diagnosis remains an ongoing challenge. To identify innovative biomarkers and develop diagnostic kits for clinical use, we integrate advanced methodologies and multidisciplinary expertise. Our approach combines various omics analyses, bioinformatics tools, and analytical techniques to identify and validate diagnostic, prognostic, and disease monitoring biomarkers. These tools are essential not only for diagnosis but also for assessing disease progression and response to therapy, particularly in high-social impact contexts.